It belongs to the group of glucocorticosteroids of local action, it has anti-inflammatory and anti-allergic effect. It inhibits the release of inflammatory mediators, increases the production of lipocortin (annexin), an inhibitor of phospholipase A2, which leads to a decrease in the formation of arachidonic acid and the products of its transformation: Pg and leukotrienes, inhibits the synthesis of metabolic products of arachidonic acid-cyclic endoperoxides, Pg, as well as a factor that activates platelets.
Reduces the formation of the chemotaxis substance (this explains the effect on the "late" allergy reaction), inhibits the development of an "immediate" allergic reaction (due to inhibition of the production of arachidonic acid metabolites and reduced release from mast cells of inflammatory mediators) and improves mucociliary transport.Under the influence of beclomethasone, the number of mast cells in the mucous membrane of the nasal cavity and paranasal sinuses decreases, edema decreases, mucus secretion, neutrophil accumulation, inflammatory exudate and cytokine production, macrophage migration is inhibited, the intensity of infiltration and granulation processes decreases, which plays a significant role in the development of allergic rhinitis. Increases the number of active beta-adrenergic receptors.
Virtually does not have mineralocorticosteroid activity and resorptive effect after intranasal administration. In therapeutic doses, it has an active local effect without the development of side effects characteristic of systemic glucocorticosteroids.
The therapeutic effect develops gradually, usually after 5-7 days of course use of beclomethasone dipropionate, in some patients - in 2-3 weeks.